<< MHAUS introduces new MH Mock Drill Training Kit to better prepare for MH emergencies | New Verizon Medical Data Exchange platform launched >>

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Published on March 4, 2010 at 1:30 AM · No Comments

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

Continued on Next page >>

National Alzheimer's plan to include more research fundingThe Obama administration wants to spend just over half a billion dollars on Alzheimer's research nex...
Stealth presents Bendavia at AHA's Cardiovascular Scientific SessionsStealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mi...
Ligand announces acquisition of CyDex PharmaceuticalsLigand Pharmaceuticals Incorporated today announced it has acquired privately held CyDex Pharmaceuti...
Gold nanoparticles show great potential for tumour targeted drug deliveryThe World Gold Council (WGC) is delighted with the successful phase 1 clinical trial of a unique nan...
Study finds association between personality, cognitive ability and neuroendocrinal dysfunction in exhaustion syndromeExhaustion syndrome, also called burnout and exhaustion depression, leaves objectively measurable ch...
Value of Japanese pharmaceutical market to increase at very modest CAGR of 1.25%Research and Markets has announced the addition of the "Japan Pharmaceuticals and Healthcare Report ...
Possible cause of chemobrain foundThanks to early diagnosis and chemotherapy, more women survive breast cancer than ever before.
D-cycloserine could help treat drug addictionScientists at the U.S. Department of Energy's Brookhaven National Laboratory provide further evidenc...
Brain inflammation may actually be a friend for Alzheimer's patientsInflammation in the brain may not be so bad after all when it comes to Alzheimer's disease.
Researchers step toward therapy for respiratory syncytial virusWhen a child under the age of 2 contracts a respiratory tract infection requiring hospitalization, o...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.